FEMASYS INC. 10-Q Summary: Quarter Ended September 30, 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Femasys Inc. is a biomedical innovator focused on women's health, specifically infertility and permanent birth control. Key products include FemaSeed (intratubal insemination), FemVue (diagnostic), and FemBloc (non-surgical permanent birth control). The company is a non-accelerated filer, smaller reporting company, and emerging growth company. As of November 13, 2025, there were 58,479,824 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 |
|---|---|---|
| Sales (Revenue) | $729,394 | $1,479,926 |
| Net Loss | $(4,194,821) | $(14,677,582) |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.46) |
| Cash and Cash Equivalents | $4,569,038 (as of Sept 30, 2025) | N/A |
| Accumulated Deficit | $(141,875,839) | N/A |
| Convertible Notes Payable (Net) | $6,507,354 | N/A |
| Inventory | $5,783,974 | N/A |
Operating Cash Flow: Net cash used in operating activities for the nine months ended September 30, 2025, was $(14,505,325). Net cash provided by financing activities was $16,055,985, driven by equity financings in June and August 2025.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 31.4% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 41.3% year-to-date, primarily driven by international sales of FemBloc and FemVue.
- Expense Reduction: Total operating expenses decreased 25.4% in Q3 2025 compared to Q3 2024, largely due to reduced R&D costs as products moved to commercialization and lower professional fees.
- Inventory Build: Inventory increased significantly from $3.05 million (Dec 31, 2024) to $5.78 million (Sept 30, 2025), reflecting preparation for commercialization.
- Financing Activity: The company completed significant equity financings in June and August 2025, raising approximately $11.8 million in net proceeds combined, and entered into a $12 million convertible note agreement in November 2025 (subsequent event).
Guidance, Outlook, Risks, and Unusual Items
Outlook and Liquidity: Management states that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year from the issuance of the financial statements. While the November 2025 financing ($12 million) and existing cash are expected to fund operations into September 2026, the company anticipates needing additional capital to complete U.S. clinical development for FemBloc and fund ongoing operations.
Key Risks:
- Nasdaq Compliance: The company received deficiency notices regarding Market Value of Listed Securities (MVLS) and Minimum Bid Price requirements. While pro forma equity from recent financings may satisfy MVLS, the stock price remains below the $1.00 minimum bid price, requiring a reverse stock split or other action by January 2026 to avoid delisting.
- Regulatory Approval: U.S. commercialization of FemBloc is contingent on FDA approval following the pivotal FINALE trial. The company received FDA IDE approval in November 2025 to continue enrollment.
- Debt Obligations: The company has significant convertible notes outstanding. The November 2025 financing proceeds are largely intended to repay the November 2023 convertible notes.
Unusual Items: Interest expense increased significantly due to the amortization of debt discounts and issuance costs related to convertible notes. The company also incurred expenses related to an "Any Market Purchase Agreement" with Alumni Capital LP.
Investor Verification Checklist
- Going Concern Status: Verify the sufficiency of the November 2025 financing ($12M) to cover the burn rate and the timeline for the next capital raise.
- Nasdaq Delisting Risk: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement or confirm the execution of a reverse stock split before the January 2026 deadline.
- FemBloc U.S. Trial Progress: Track enrollment and data readouts from the pivotal FINALE clinical trial, which is critical for U.S. revenue generation.
- Debt Conversion: Review the terms of the November 2023 and November 2025 convertible notes, specifically conversion prices and potential dilution to existing shareholders.
- Inventory Valuation: Assess the $5.8 million inventory balance against actual sales velocity to ensure no impairment is required.